KRAS and colorectal cancer: PrP&lt;sup&gt;C&lt;/sup&gt;-Neutralizing Antibody Confers an Additive Benefit in Combination with 5-Fluorouracil in KRAS-Mutant Colorectal Cancer Models, Associated with Reduced RAS-GTP and AKT/ERK Phosphorylation.